DXR logo

Daxor Corporation Common Stock


DXR: Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.


Show DXR Financials

Consumer Interest
SEC Filings

Recent trades of DXR by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by DXR's directors and management

Government lobbying spending instances

  • $20,000 Jan 20, 2023 Issue: Defense
  • $10,000 Oct 17, 2022 Issue: Defense
  • $30,000 Jul 19, 2022 Issue: Defense
  • $20,000 Oct 12, 2017 Issue: Defense Veterans
  • $10,000 Jul 14, 2017 Issue: Veterans Defense
  • $10,000 Apr 19, 2017 Issue: Defense Veterans
U.S. Patents

New patents grants

  • Patent Title: Blood volume analysis with volume-aware blood component measures and treatment Dec. 21, 2021
  • Patent Title: Automated blood analyzer Apr. 07, 2015
  • Patent Title: Automated total body albumin analyzer Apr. 07, 2015

Number of mentions of DXR in WallStreetBets Daily Discussion

DXR News

Recent insights relating to DXR

CNBC Recommendations

Recent picks made for DXR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in DXR

Corporate Flights

Flights by private jets registered to DXR